MicroRNAs (miRNAs) belong to a family of small non-proteincoding RNAs that regulate expression of multiple target genes and are involved in many fundamental biological processes, such as embryonic development, cell proliferation, differentiation and apoptosis [1] [2] [3] [4] [5] . miRNAs promote degradation of mRNA or prevent translation of the target genes, and they can be viewed as endogenous mediators of RNA interference (RNAi) 1 . miRNAs have been identified as crucial regulators of differentiation of various cell types, including neuronal cells in the central nervous system (CNS) and myeloid cells in the innate immune system 2, 6 . Furthermore, deregulated expression of specific miRNAs is associated with many pathological processes, including viral infection, heart disease and cancer [7] [8] [9] [10] .
Macrophages are traditionally subdivided into tissue-resident cells (such as microglia in the CNS), which are present in normal tissues, and activated inflammatory peripheral macrophages, which are known to migrate to the site of inflammation during processes such as EAE [11] [12] [13] [14] [15] [16] . EAE is a mouse model of the human disease multiple sclerosis, characterized by autoimmune inflammation of the CNS associated with microglia activation and infiltration of encephalitogenic T cells and leukocytes from the periphery. In contrast to other tissue-specific resident macrophages, microglia show a resting phenotype with low expression of both the pan-leukocyte marker CD45 and MHC class II (CD45 low MHC class II low ) in the normal CNS, but the mechanisms maintaining this unique phenotype remain unknown. Our goal was to identify miRNAs that are specifically expressed in microglia and contribute to their phenotypes.
We found that miR-124, the most abundant brain-specific miRNA that regulates neuronal differentiation during CNS development and adult neurogenesis [17] [18] [19] [20] , is also expressed in microglia. Here we show that miR-124 acts both as a key regulator of microglia quiescence in the CNS and as a new modulator of monocyte and macrophage activation in the periphery during EAE.
RESULTS miR-124 is highly expressed by CNS-resident microglia
To identify miRNAs that are enriched in microglia, we selected 31 miRNAs known to be expressed in immune cells and in the CNS 21 and analyzed their expression in sorted CD11b + F4/80 + macrophages from different organs of healthy adult mice by real-time quantitative RT-PCR (qRT-PCR; Supplementary Data and Supplementary Table 1 ). This analysis revealed that only resident macrophages from brain and spinal cord (microglia) expressed miR-124 (Fig. 1a) , whereas myeloid-specific miR-223 (refs. 6, 22) was expressed in the macrophages in the periphery, but not in the microglia (Fig. 1b) . The level of miR-124 expression in microglia was comparable to that in cultured cortical neurons (Supplementary Data and Supplementary Fig. 1 ), the cells expressing the highest miR-124 levels 21, 23, 24 .
We next investigated expression of specific miRNAs, including miR-124, in microglia during EAE, a disease characterized by microglia activation and infiltration of peripheral macrophages into the CNS. As there are no markers to distinguish microglia from peripheral macrophages that migrate into the CNS during inflammation, we used chimeric mice to discriminate between these populations. In these chimeras, microglia and peripheral macrophages can be separated easily by FACS (Fig. 1c , Supplementary Data and Supplementary Fig. 2 ). In this study, we refer to cells expressing CD11b + F4/80 + as 'macrophages' even though they may include small numbers of CD11b + CD11c + F4/80 + myeloid dendritic cells. Peripheral macrophages may also be contaminated by small numbers of GFP + microglia that enter the CNS during reconstitution 14 . We measured miR-124 expression in sorted populations of CD11b + F4/80 + GFP − microglia and CD11b + F4/80 + GFP + CNS-infiltrating peripheral macrophages of healthy chimeras and chimeric mice with EAE at different stages of disease (Fig. 1d , Supplementary Data and Supplementary Table 1 ). In microglia, miR-124 expression decreased by ~70% during the course of the disease, compared to healthy chimeras (Fig. 1d) . Peripheral macrophages, however, began to express low levels of miR-124 during onset and in the recovery phase (Fig. 1d, days 14 and 40 ). These results demonstrate that miR-124 is strongly expressed in microglia both in the normal CNS and during EAE; it is undetectable in macrophages in the periphery but is slightly induced in CNSinfiltrating peripheral macrophages during the onset and recovery phases of the disease.
Activated microglia downregulate miR-124
In our model, microglia in healthy chimeric mice had a CD45 low MHC class II − phenotype, whereas during the onset and peak of EAE, microglia upregulated CD45 and MHC class II (Fig. 2a ). During recovery, the level of MHC class II in microglia returned to normal, but a subset of cells remained CD45 hi , suggesting some residual level of activation. Peripheral macrophages in the CNS of healthy mice showed an activated CD45 hi MHC class II hi phenotype, which was consistent with previous studies 25 . Most of the peripheral macrophages that infiltrated the CNS during EAE onset and at the peak of disease also showed an activated CD45 hi MHC class II + phenotype (Fig. 2a) . During onset of EAE, ~40% of peripheral macrophages showed a partially deactivated MHC class II − phenotype, whereas during recovery, ~40% of peripheral macrophages became CD45 low MHC class II − (Fig. 2a) . This suggests further deactivation, which is in agreement with recent studies 26 . The miR-124 expression pattern (downregulation in microglia at EAE onset when the cells become activated, and upregulation in peripheral macrophages at EAE onset and recovery when the subset of cells deactivates) suggests a link between miR-124 and the activation state of microglia and macrophages (Figs. 1 and 2). We therefore further compared the levels of miR-124 expression in the following four populations sorted from the CNS of mice with EAE (onset of disease): resting CD45 low MHC class II − microglia, activated CD45 int-hi MHC class II + microglia (MHC class II + microglia have an intermediate or high level of CD45 expression), activated CD45 hi MHC class II + peripheral macrophages, and deactivated CD45 MHC class II − peripheral macrophages (MHC class II − peripheral macrophages have an intermediate or high level of CD45 expression). The highest level of miR-124 expression was observed in resting CD45 low MHC class II − microglia, whereas activated MHC class II + microglia expressed a 60% lower level of miR-124 (Fig. 2b) . Activated MHC class II + peripheral macrophages expressed very low levels of miR-124, whereas deactivated MHC class II − macrophages upregulated miR-124 by 4.2-fold (Fig. 2b) . To investigate whether activated microglia downregulate miR-124 in vitro, we used microglia isolated from healthy adult mice, culturing them for 6 h in media alone, with the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-γ (IFN-γ), or with liposaccharide (LPS) and IFN-γ; these three agents are known to activate microglia. Microglia cultured with GM-CSF and IFN-γ or with LPS and IFN-γ downregulated miR-124 compared to ex vivo-isolated cells or cells cultured in media alone (Fig. 2c) . During mouse prenatal and postnatal development, microglia showed an activated phenotype with a low level of miR-124 expression (Supplementary Data and Supplementary Fig. 3 ). Collectively, these data demonstrate that miR-124 expression correlates inversely with the activation state of microglia and macrophages in the CNS.
miR-124 deactivates bone marrow-derived macrophages in vitro
In the next series of experiments, we asked whether transfection of peripheral macrophages with miR-124 resulted in downregulation of activation markers. We transfected bone marrow-derived macrophages (BMDMs) with either miR-124 or negative-control RNA (control miRNA). BMDMs transfected with negative control showed an activated phenotype, with high protein expression of surface markers CD45, CD11b, F4/80, MHC class II and CD86. Transfection of BMDMs with miR-124 resulted in downregulation of CD45, CD11b, F4/80, MHC class II and CD86 (Fig. 3a,b) .
Transfection of macrophages with miR-124 also inhibited expression of TNF-α (Fig. 3c) and inducible nitric oxide synthase (Fig. 3d) by these cells, and upregulated both the anti-inflammatory cytokine TGF-β1 (Fig. 3d,e) and markers of alternatively activated (M2) macrophages arginase I and FIZZ1 (Fig. 3d) .
Transfection with miR-124 also resulted in a reduced number of proliferating cells and altered cell morphology (Supplementary Data and Supplementary Fig. 4 ). Further analysis of the extent and mechanisms of macrophage transfection is described in Supplementary Data ( Supplementary  Figs. 5 and 6 ).
miR-124 downregulates C/EBP- and PU.1 Having found that miR-124 deactivated macrophages (Fig. 3) , we investigated the mechanism underlying this effect. Using the TargetScan algorithm 27 , we performed in silico analysis of mRNA targets predicted for miR-124. C/EBP-α, a master transcription factor involved in differentiation of myeloid cells 28, 29 , was predicted as a putative target, with three conserved miR-124 binding sites within its 3′ untranslated region (UTR; Fig. 4a ). C/EBP-α expression was reduced in miR-124-transfected BMDMs by 50-70% on the protein level ( Fig. 4b) and by 50% on the mRNA level (Fig. 3d) . Two-color flow cytometry further confirmed that transfection of macrophages with miR-124 resulted in downregulation of both CD45 and C/EBP-α (Fig. 4c) , and indicated that the C/EBP-α − phenotype corresponded to the CD45 low phenotype of macrophages. Expression of the transcription factor PU.1, which is regulated by C/EBP-α and is also required for differentiation of monocytic-lineage cells [29] [30] [31] , was downregulated by miR-124 as well (Fig. 4c) . Quantification of the four experiments shows that miR-124 overexpression decreased the proportion of CD45 hi C/EBP-α + and CD45 hi PU.1 + cells by 70% and 80%, respectively (Fig. 4d) .
Next we sought to confirm, using a luciferase reporter system, that miR-124 directly binds the mRNA encoding C/EBP-α and downregulates expression of this protein. The mouse neuroblastoma cell line NIE115, which does not express C/EBP-α and has a low level of endogenous miR-124 expression, was transfected with a construct containing the full-length C/EBP-α 3′ UTR sequence downstream of firefly luciferase. The transfected cells showed luciferase activity, which the cotransfection with miR-124 inhibited by 72% (Fig. 4e) . Mutations of this reporter construct within two predicted miR-124 binding sites (C/EBP-αmut1-2) substantially reduced the luciferase responsiveness to miR-124, and mutations within all three predicted sites (C/EBP-αmut1-3) nearly abolished it (Fig. 4e) . These data confirm that miR-124 directly targets the mRNA encoding C/EBP-α and reduces expression of this protein.
Our experiments showed that miR-124 overexpression causes downregulation of transcription factor PU.1 (Fig. 4c) and activation markers CD45, MHC class II and CD86 (Fig. 3a,b) . According to the target-prediction analysis in silico, miR-124 does not directly regulate either PU.1 mRNA or mRNAs for activation markers CD45, CD11b, F4/80, MHC class II and CD86. As C/EBP-α binds the promoter region of PU.1 and induces its transcription 30, 31 , we hypothesized that miR-124 downregulates PU.1 indirectly through the inhibition of C/EBP-α. To test this hypothesis, we used mice with a conditional knockout of the Cebpa gene. This conditional knockout reduced levels of C/EBP-α protein, which resulted in reduced expression of PU. Supplementary Fig. 7 ). These data suggest that miR-124 controls multiple markers of macrophage activation by direct inhibition of C/EBP-α and its downstream transcription factor PU.1.
miR-124 inhibits EAE and reduces CNS inflammation
As miR-124 expression regulated macrophage activation, we investigated whether systemic administration of miR-124 in vivo affects the course of EAE. Administration of miR-124 during the preclinical stage of EAE (beginning on day 7 after disease induction) completely prevented disease symptoms (Fig. 5a) . Treatment of mice with miR-124 at the onset of EAE (starting day 13 after EAE induction) also substantially ameliorated clinical symptoms and enhanced recovery (Fig. 5b) . These studies were carried out in C57BL/6 mice. We then investigated whether miR-124 suppressed EAE in other strains. Disease symptoms were also substantially ameliorated in both EAEprone SJL mice as well as in Ifng −/− mice, which have a more severe form of EAE (Supplementary Data and Supplementary Fig. 8a,b) .
To assess changes in inflammatory responses in mice with EAE treated with miR-124, we sacrificed groups of four or five mice at day 21 (when the control group had peak EAE) and isolated mononuclear cells from the CNS and spleens. We detected CD11b + CD45 hi peripheral macrophages and activated microglia (Fig. 5c , control miRNA, region R2), and CD11b − CD45 hi leukocytes (Fig. 5c , control miRNA, region R3), in the CNS of mice from the control group. In contrast, the mice treated with miR-124 had primarily CD11b + CD45 low resting microglia (Fig. 5c, miR-124 , region R1) and no signs of microglia activation or leukocyte infiltration in the CNS (Fig. 5c, miR-124, regions R2 and R3 ). This suggests that peripheral administration of miR-124 suppressed EAE symptoms and leukocyte infiltration in the CNS (Supplementary Data and Supplementary Table 2 ). Figure 5d shows how the treatment with miR-124 decreased the absolute numbers of lymphocytes, CD4 T cells and macrophages and activated CD45 hi microglia in the CNS. Inflammatory lesions containing nucleated and CD11b + cells in the white matter of the lumbar spinal cord were evident in the control group but undetectable in the miR-124-treated mice (Fig. 5e) . Thus, treatment of mice with miR-124 ameliorated both EAE symptoms and inflammation in the CNS.
We next assessed whether amelioration of EAE symptoms was due to the reduced level of C/EBP-α expression. Intravenously injected small interfering RNA (siRNA) specific for C/EBP-α had similar effects on disease symptoms, whereas mutant miR-124 lacking the C/EBP-α mRNA binding sequence had no effect on the disease score (Supplementary Data and Supplementary Fig. 9a) . Finally, we found that conditional knockout of the Cebpa gene also ameliorated EAE (Supplementary Data and Supplementary Fig. 9b) . Subsequent experiments showed that peripheral administration of miR-124 during EAE directly affected macrophages and deactivated them, and indirectly reduced the activation of autoimmune CD4 T cells (Supplementary Data, Supplementary Figs. 10-15 and Supplementary Table 3) .
Effect of miR-124 inhibitors on microglia and macrophages
To further investigate our hypothesis that expression of miR-124 is required for microglia to maintain the quiescent CD45 low MHC class II low phenotype in the normal CNS, we performed miR-124 knockdown experiments in vivo and in vitro. To knock down miR-124 in vivo, we injected an miR-124 antisense oligonucleotide inhibitor (anti-miR-124) intracranially (Supplementary Fig. 16a ). When injected into C57BL/6→Cx3cr1 GFP/+ chimeric mice that express GFP in microglia but not in peripheral macrophages, anti-miR-124 induced the activation of CD11b + GFP + microglia and altered their morphology (Supplementary Data and Supplementary Fig. 16b-e) .
As ex vivo-isolated adult microglia are not durable in long-term cultures, ex vivo cultures are unsuitable for studying relatively longterm effects of the miRNA inhibitors. We therefore chose a different approach. We hypothesized that macrophages upregulate miR-124 under the influence of the CNS microenvironment by receiving specific signals from CNS stromal cells such as astrocytes and neurons, and thus these macrophages could be used for miR-124 inhibition experiments. To test this hypothesis, we cocultured GFP + BMDMs with either an astroglial or neuronal cell line. In these cocultures, the macrophages acquired a deactivated microglia-like phenotype, as indicated by downregulation of both CD45 and MHC class II (Fig. 6a) and upregulation of miR-124 (Fig. 6b) . This coculture system allowed us to investigate whether inhibition of miR-124 affected the expression of MHC class II and CD45 in macrophages. Using the coculture system, we found that transfection of macrophages with anti-miR-124 attenuated the downregulation of MHC class II and CD45 (Fig. 6c-e) .
It also inhibited the development of the ramified microglia-like morphology in GFP + macrophages cocultured with astroglial and neuronal lines (data not shown). These data demonstrate that miR-124 has a role in maintaining the quiescent phenotype of microglia in the normal CNS, and this phenotype is driven by the paracrine interaction of microglia with local stromal cells.
DISCUSSION
Our investigation provides new insights into the role of CNS-specific miR-124 in the function of normal microglia and the control of macrophage activation during inflammation. We have demonstrated that miR-124 directly inhibits expression of the C/EBP-α transcription factor, which results in downregulation of PU.1, another master regulator of monocytic cell differentiation and decreases expression of the macrophage activation markers CD45, CD11b, F4/80, MHC class II and CD86. It has previously been shown that C/EBP-α directly activates transcription of PU.1 in monocytes 30 , which, in turn, can induce expression of CD45, CD11b, F4/80 and MHC class II 32, 33 . Moreover, PU.1 controls proliferation of macrophages by upregulating the receptor for M-CSF 34 . We also found that miR-124 inhibited expression of TNF-α in macrophages. It has previously been shown that the TNF receptor (TNFR1) is a direct downstream target for C/EBP-α and C/EBP-β 35 , and that TNF-α and TNFR1 may enhance each other's expression by an autocrine-paracrince mechanism 36, 37 . Normal adult microglia do not express C/EBP-α, but this transcription factor can be induced during inflammation 38 . In our experiments, activated microglia downregulated miR-124, and high levels of C/EBP-α expression were associated with the activated CD45 hi phenotype. As BMDMs with an inactivated Cebpa gene closely mimicked the phenotype of BMDMs overexpressing miR-124, we assume that C/EBP-α is the main miR-124 target in the monocytic-lineage cells. miR-124 is known to be expressed in the CNS by neuronal cells 23, [39] [40] [41] . It promotes differentiation of neuronal progenitors to mature neurons by targeting small C-terminal domain phosphatase-1 and polypyrimidine tract-binding protein-1 that repress expression of neuronal genes in non-neuronal cells 18, 20, 40 . It has been shown with human HeLa cells and synoviocytes that miR-124 can regulate expression of multiple target genes, including those encoding CDKs and MCP-1 (refs. 17,42) . In addition, miR-124 inhibits proliferation and induces differentiation of medulloblastoma and glioblastoma cancer cells, which originate from immature neural cells 43, 44 . We found that miR-124 is also expressed in microglia of the normal CNS, where it has a role in maintaining the cells in a quiescent state, as shown in our in vitro and in vivo knockdown experiments. Similarly to its function in neural cells, miR-124 may restrict proliferation of microglia and promote differentiation of monocytes and macrophages into adult microglia. Therefore, miR-124 may be viewed as a master regulator of differentiation of various cell types in the CNS during development. In the case of pathological events such as brain cancer or inflammation, when miR-124 is downregulated, treatment with miR-124 may have a beneficial effect by restricting proliferation, inducing differentiation of the immature CNS cells into mature phenotypes and by deactivating macrophages. Indeed, we found that deactivation of macrophages by intravenous injection of miR-124 led to suppression of EAE in three different mouse models of the disease.
Transfection of macrophages with miR-124 resulted in downregulation of markers and cytokines associated with the phenotype of the classically activated (M1) proinflammatory macrophages CD86, MHC class II, TNF-α and inhibitor of nitric oxide synthase, whereas cytokines and markers associated with the phenotype of alternatively activated (M2) regulatory macrophages-TGF-β1, arginase I and FIZZ1-were upregulated. These data suggest that miR-124 not only deactivates macrophages but also skews their polarization from an M1 toward an M2 phenotype. These results are consistent with our observations that quiescent microglia show properties of M2 macrophages and that M2 macrophages are crucial for the suppression of EAE 45 . Our extensive analysis showed that in vivo administration of miR-124 directly affected macrophages, and this, in turn, resulted in deficient activation of encephalitogenic T cells (Supplementary Discussion). In summary, our findings demonstrate that miR-124 has a key role in inhibiting macrophage activation and promoting microglial differentiation under physiological conditions in the CNS microenvironment. Furthermore, in vivo administration of miR-124 suppresses EAE by affecting macrophages, and this treatment could also be applied to other inflammatory diseases associated with macrophage activation, such as rheumatoid arthritis, type 1 diabetes and atherosclerosis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
